OptiNose, Inc. (OPTN)
USD 9.4
(0.11%)
USD 9.4
(0.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.48 Million USD | 53.55% |
| 2022 | -76.39 Million USD | 6.44% |
| 2021 | -81.65 Million USD | 16.96% |
| 2020 | -98.33 Million USD | 9.74% |
| 2019 | -108.94 Million USD | -2.14% |
| 2018 | -106.65 Million USD | -118.11% |
| 2017 | -48.9 Million USD | -316.26% |
| 2016 | 22.61 Million USD | 179.87% |
| 2015 | -28.31 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.06 Million USD | -41.14% |
| 2024 Q2 | -7.58 Million USD | 46.11% |
| 2023 Q3 | -9.29 Million USD | -453.92% |
| 2023 Q4 | -9.96 Million USD | -7.24% |
| 2023 Q2 | 2.62 Million USD | 114.08% |
| 2023 FY | -35.48 Million USD | 53.55% |
| 2023 Q1 | -18.65 Million USD | -7.63% |
| 2022 Q4 | -17.33 Million USD | -15.94% |
| 2022 Q3 | -14.94 Million USD | 22.94% |
| 2022 Q2 | -19.39 Million USD | 23.42% |
| 2022 Q1 | -25.33 Million USD | -62.15% |
| 2022 FY | -76.39 Million USD | 6.44% |
| 2021 Q3 | -17.11 Million USD | 27.17% |
| 2021 Q2 | -23.5 Million USD | 9.79% |
| 2021 Q1 | -26.05 Million USD | -9.17% |
| 2021 FY | -81.65 Million USD | 16.96% |
| 2021 Q4 | -15.62 Million USD | 8.73% |
| 2020 Q4 | -23.86 Million USD | -12.49% |
| 2020 Q2 | -25.85 Million USD | 10.41% |
| 2020 Q3 | -21.21 Million USD | 17.94% |
| 2020 FY | -98.33 Million USD | 9.74% |
| 2020 Q1 | -28.85 Million USD | -15.44% |
| 2019 FY | -108.94 Million USD | -2.14% |
| 2019 Q2 | -27.37 Million USD | 5.18% |
| 2019 Q1 | -28.87 Million USD | -9.45% |
| 2019 Q4 | -24.99 Million USD | 13.23% |
| 2019 Q3 | -28.8 Million USD | -5.23% |
| 2018 Q1 | -30.57 Million USD | -56.37% |
| 2018 FY | -106.65 Million USD | -118.11% |
| 2018 Q4 | -26.38 Million USD | -5.01% |
| 2018 Q3 | -25.12 Million USD | -2.2% |
| 2018 Q2 | -24.58 Million USD | 19.6% |
| 2017 Q1 | -8.07 Million USD | -44.51% |
| 2017 Q2 | -8.2 Million USD | -1.65% |
| 2017 Q3 | -13.06 Million USD | -59.21% |
| 2017 Q4 | -19.55 Million USD | -49.61% |
| 2017 FY | -48.9 Million USD | -316.26% |
| 2016 FY | 22.61 Million USD | 179.87% |
| 2016 Q2 | -23.79 Million USD | -165.57% |
| 2016 Q3 | -6.1 Million USD | 74.34% |
| 2016 Q4 | -5.58 Million USD | 8.48% |
| 2016 Q1 | 36.29 Million USD | 0.0% |
| 2015 FY | -28.31 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 83.043% |
| Theratechnologies Inc. | -23.95 Million USD | -48.111% |
| Safety Shot Inc | -15.08 Million USD | -135.251% |
| Cosmos Health Inc. | -18.54 Million USD | -91.359% |
| Cronos Group Inc. | -73.96 Million USD | 52.026% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 96.46% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 15.915% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 817.553% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -475.737% |
| ProPhase Labs, Inc. | -16.78 Million USD | -111.435% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -633.878% |
| Dynavax Technologies Corporation | -6.38 Million USD | -455.376% |
| Radius Health, Inc. | -25.79 Million USD | -37.579% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -1045.155% |
| Alvotech | -551.73 Million USD | 93.569% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -687.453% |
| Alpha Teknova, Inc. | -36.78 Million USD | 3.526% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 74.596% |
| SCYNEXIS, Inc. | 67.04 Million USD | 152.927% |
| Harrow Health, Inc. | -24.41 Million USD | -45.357% |
| Biofrontera Inc. | -20.13 Million USD | -76.26% |
| DURECT Corporation | -27.62 Million USD | -28.45% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 2796.277% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 288.95% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 248.365% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -350.864% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -465.077% |
| SIGA Technologies, Inc. | 68.06 Million USD | 152.128% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 395.372% |
| Shineco, Inc. | -22.44 Million USD | -58.06% |
| Phibro Animal Health Corporation | 2.41 Million USD | 1568.667% |
| Procaps Group S.A. | 42.54 Million USD | 183.411% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -245.233% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -724.834% |
| Viatris Inc. | 54.7 Million USD | 164.868% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -687.453% |
| Rockwell Medical, Inc. | -8.43 Million USD | -320.465% |
| Incannex Healthcare Limited | -18.45 Million USD | -92.226% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -123.952% |
| Tilray Brands, Inc. | -244.98 Million USD | 85.516% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 173.685% |
| PetIQ, Inc. | 2.13 Million USD | 1765.087% |
| Silver Spike Investment Corp. | 7.34 Million USD | 583.413% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 114.21% |
| Journey Medical Corporation | -3.85 Million USD | -820.919% |
| Alimera Sciences, Inc. | -20.13 Million USD | -76.252% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -334.671% |
| Assertio Holdings, Inc. | -331.94 Million USD | 89.31% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -438.215% |
| Embecta Corp. | 70.4 Million USD | 150.402% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -76.908% |
| Procaps Group, S.A. | 42.54 Million USD | 183.411% |
| PainReform Ltd. | -9.34 Million USD | -279.741% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 77.861% |
| Hempacco Co., Inc. | -13.12 Million USD | -170.324% |
| Talphera, Inc. | -18.39 Million USD | -92.874% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 184.574% |
| Alvotech | -551.73 Million USD | 93.569% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 110.862% |
| Kamada Ltd. | 8.28 Million USD | 528.332% |
| Indivior PLC | 2 Million USD | 1874.15% |
| Currenc Group, Inc. | -15.3 Million USD | -131.816% |
| Evoke Pharma, Inc. | -7.79 Million USD | -355.36% |
| Flora Growth Corp. | -57.03 Million USD | 37.788% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -76.908% |
| Evolus, Inc. | -61.68 Million USD | 42.477% |
| HUTCHMED (China) Limited | 100.78 Million USD | 135.208% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 125.797% |
| Akanda Corp. | -32.27 Million USD | -9.939% |